본문 바로가기
  • Home

A Randomized single blind controlled clinical trial on safety and efficacy of a Unani formulation (Itrifal-e-Sagheer) in dyslipidemia

  • CELLMED
  • Abbr : CellMed
  • 2020, 10(1), pp.8-8
  • DOI : 10.5667/tang.2020.0008
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : December 25, 2019
  • Accepted : January 14, 2020
  • Published : February 28, 2020

Sazid Alam 1 MD Anzar Alam 2 Ghulamuddin Sofi 3 Mohd. Qudratullah Khan 4 Shabnam Ansari 5

1Department of Moalajat (Medicine), Sufia Unani medical college hospital and research center
2Department of Moalajat, National Institute of Unani medicine
3Department of Ilmul Advia, National Institute of Unani medicine
4Luqman Unani medical college hospital and research center
5Jamia Millia Islamia

Candidate

ABSTRACT

Aim:‘Itrifal-e-Sagheer’, a compound Unani formulation has been indicated in disease conditions simulating dyslipidemia. The present study was done to substantiate the efficacy of ‘Itrifal-e-Sagheer’ in dyslipidemia on scientific parameters. Materials and methods: A randomized, single blind, controlled, clinical trial was carried out on 30 patients of dyslipidemia who were randomly allocated into test (n = 15) or control (n = 15) groups. The test drug, Itrifal-e-Sagheer and control drug, Abana® were given to respective group for 45 days along with lifestyle modification. Results: The test drug significantly alleviated the symptoms of subjective parameters (palpitation, breathlessness and weight gain) (p<0.05). There was statistically significant reduction in lipid profile of the patients in test group (p<0.05) than control drug treatment. Conclusion: The study evidenced that Itrifal-e-Sagheer is potentially effective and safe in the treatment of dyslipidemia. However, a multicentric study with robust study design is required to generalize the results.

Citation status

* References for papers published after 2022 are currently being built.